Setmelanotide (obesity and the control of hunger associated with deficiency in POMC, PCSK1 or LEPR, adults and children ≥ 6 years of age)

Subject:

• Active Substance: Setmelanotide
• Name: Imcivree^®
• Therapeutic area: Obesity and the control of hunger
• Pharmaceutical company: Rhythm Pharmaceuticals Inc.
   

Time table:

• Start: 01.06.2022
• Final decision by G-BA: 01.12.2022

Final decision:

• Hint for a non-quantifiable additional benefit